Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b study of ATOR-1015 in malignant melanoma

Next Previous
X
Search
Trial Profile

A Phase 1b study of ATOR-1015 in malignant melanoma

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 11 Sep 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ATOR-1015 (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Sponsors Alligator Bioscience

    • Most Recent Events

    • 11 Sep 2020 New trial record
    • 09 Sep 2020 According to an Alligator Bioscience media release, the company announced today updated timelines indicating 3-6 months delay for this planned Phase Ib study with ATOR-1015. The start of the Phase Ib expansion in malignant melanoma will be pushed into 2021 due to study amendments to adjust for the observed reactions. Recruitment will start as soon as regulatory approval has been obtained.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top